Akero Therapeutics, Inc.
US ˙ NasdaqGS ˙ US00973Y1082
DIESES SYMBOL IST NICHT MEHR AKTIV

SecurityAKRO / Akero Therapeutics, Inc.
InstitutionD. E. Shaw & Co., Inc.
ManagerDE Shaw
Latest Disclosed Ownership0 shares
Latest Disclosed Value $ 0
D. E. Shaw & Co., Inc. ownership in AKRO / Akero Therapeutics, Inc.

On February 17, 2026 - D. E. Shaw & Co., Inc. filed a 13F-HR form disclosing ownership of 0 shares of Akero Therapeutics, Inc. (US:AKRO) valued at $0 USD as of December 31, 2025. The entity filed a previous 13F-HR on November 14, 2025 disclosing 17,572 shares of Akero Therapeutics, Inc.. The current value of the position is $0 USD.

D. E. Shaw & Co., Inc. has a history of taking positions in derivatives of the underlying security (AKRO) in the form of stock options. The firm currently holds call options representing 0 of underlying shares valued at $0 USD and put options representing 0 of underlying shares valued at $0 USD .

Note: prior versions of this page mistakenly stated that the share values represented the number of options, not the number of underlying shares. For more information on the data backing these reports, please see the SEC document Frequently Asked Questions About Form 13F.

Institutional Ownership: 13F and NPORT Filings

The Security and Class in the table below are shown exactly as filed by the investor. We do our best to track continuity of investments through acquisitions, and this will be reflected in the table as changes in names. In addition to descriptive data, performance of the investment is shown over time. To calculate quarterly performance, we first calculate cost basis of the shares purchased during the quarter, then use that to calculate gross profit. Quarterly return is Gross Profit / Starting Portfolio value.

Note that cost basis is calculated and stored in thousands, so small quarterly changes in shares frequently result in a cost basis of zero.

Upgrade to unlock premium data and export to Excel .

Institutional Put/Call Ratios
(Premium Subscription Required)

In addition to reporting standard equity and debt issues, institutions with more than 100MM assets under management must also disclose their put and call option holdings. Since put options generally indicate negative sentiment, and call options indicate positive sentiment, we can get a sense of the overall institutional sentiment by plotting the ratio of puts to calls. The chart to the right plots the historical put/call ratio for this instrument.

Using Put/Call Ratio as an indicator of investor sentiment overcomes one of the key deficiencies of using total institutional ownership, which is that a significant amount of assets under management are invested passively to track indices. Passively-managed funds do not typically buy options, so the put/call ratio indicator more closely tracks the sentiment of actively-managed funds.

AKRO / Akero Therapeutics, Inc. Historical Put/Call Ratio
Disclosed Equity Positions (from 13F/NPORT Filings)
File
Date
Effective
Date
Form Security Class ID Avg Price
Paid (Est)
Reported
Shares
ΔShares ΔShares
(%)
Reported
Value
(x1000)
ΔValue
(%)
Alloc
(%)
ΔAlloc ΔAlloc (%) Cost Basis
(x1000)
Unrealized
Gain/Loss
(x1000)
2026-02-17 2025-12-31 13F AKERO THERAPEUTICS COM 00973Y108 0 -100.00 0
2025-11-14 2025-09-30 13F AKERO THERAPEUTICS COM 00973Y108 17,572 -36,294 -67.38 834 -70.98 0.0005
2025-08-14 2025-06-30 13F AKERO THERAPEUTICS COM 00973Y108 53,866 41,707 343.01 2,874 484.15 0.0020
2025-05-15 2025-03-31 13F AKERO THERAPEUTICS COM 00973Y108 12,159 -23,650 -66.04 492 -50.60 0.0004
2025-02-14 2024-12-31 13F AKERO THERAPEUTICS COM 00973Y108 35,809 -80,573 -69.23 996 -70.16 0.0007
2024-11-14 2024-09-30 13F AKERO THERAPEUTICS COM 00973Y108 116,382 -199,335 -63.14 3,339 -54.93 0.0029
2024-08-14 2024-06-30 13F AKERO THERAPEUTICS COM 00973Y108 315,717 -91,408 -22.45 7,407 -27.98 0.0069
2024-05-15 2024-03-31 13F AKERO THERAPEUTICS COM 00973Y108 407,125 196,165 92.99 10,284 108.79 0.0088
2024-02-14 2023-12-31 13F AKERO THERAPEUTICS COM 00973Y108 210,960 74,062 54.10 4,926 -28.87 0.0043
2023-11-14 2023-09-30 13F AKERO THERAPEUTICS COM 00973Y108 136,898 -274,221 -66.70 6,924 -63.93 0.0072
2023-08-14 2023-06-30 13F AKERO THERAPEUTICS COM 00973Y108 411,119 43,108 11.71 19,195 36.33 0.0196
2023-05-15 2023-03-31 13F AKERO THERAPEUTICS COM 00973Y108 368,011 74,167 25.24 14,080 -12.56 0.0151
2023-02-14 2022-12-31 13F AKERO THERAPEUTICS COM 00973Y108 293,844 254,821 653.00 16,103 1,111.59 0.0178
2022-11-14 2022-09-30 13F AKERO THERAPEUTICS COM 00973Y108 39,023 28,353 265.73 1,329 1,215.84 0.0016
2022-08-15 2022-06-30 13F AKERO THERAPEUTICS COM 00973Y108 10,670 10,670 101 0.0001
Disclosed Call Options
File
Date
Effective
Date
Form Security Class ID Opt Avg Share
Price
Shares ΔShares
(%)
Value
(x1000)
ΔValue
(%)
Prior Allocation
(%)
Allocation
(%)
ΔAllocation
(%)
Cost Basis
(x1000)
Profit
(x1000)
Return
(%)
2025-02-14 2024-12-31 13F AKERO THERAPEUTICS COM Call 0 -100.00 0 -100.00 n/a n/a n/a
2024-11-14 2024-09-30 13F AKERO THERAPEUTICS COM Call 9,000 258 n/a n/a n/a
Disclosed Put Options
File
Date
Effective
Date
Form Security Class ID Opt Avg Share Price Shares ΔShares
(%)
Value
(x1000)
ΔValue
(%)
Prior Allocation
(%)
Allocation
(%)
ΔAllocation
(%)
Cost Basis
(x1000)
Profit
(x1000)
Return
(%)
2023-11-14 2023-09-30 13F AKERO THERAPEUTICS COM Put 0 -100.00 0 -100.00 n/a n/a n/a
2023-08-14 2023-06-30 13F AKERO THERAPEUTICS COM Put 20,000 934 n/a n/a n/a
Legend
Shares
The total number of shares held by the institution at the end of the reporting period (the effective date). This is provided in the filing.
Value
The total value of the shares as of the effective date. This is provided in the filing.
Avg. Share Price
The weighted average share price of the shares held by the institution. We use FIFO accounting to determine this price
Class
This is the security class as indicated by the filer. There are a variety of values for this field. Common values include "EC" = equity common, "EP" - equity preferred
Allocation (%)
The percent of the institution's portfolio that this position represents. This is provided in NPORT filings. For 13F filings, we calculate it.
Change in Allocation
The change in allocation from the prior reporting period. This is calculated as current allocation - prior allocation.
Change in Allocation (%)
The percent change in allocation from the prior reporting period. This is calculated as (current allocation - prior allocation) / prior allocation.
Cost Basis
The total cost of the shares held. This is calculated as reported shares * avg. share price
Unrealized Gain/Loss
This is the market value of the position as of the effective date minus the cost basis.